George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on September 22, 2026, disclosing the sale of 774 ordinary shares on September 21, 2026, to cover tax withholding obligations tied to a restricted stock unit vesting event.

Key Highlights

  • Shares sold: 774 ordinary shares disposed of on September 21, 2026, at a price of $8.33 per share.
  • Purpose of sale: Shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units on September 18, 2026.
  • Rule 10b5-1 plan: According to the filing, the sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan and "do not represent discretionary trades."
  • Remaining ownership: Following the transaction, Cardoza directly beneficially owned 308,318 ordinary shares.
  • Transaction code: The disposal was coded "S" (open-market sale) in Table I of the filing.

SOPHiA GENETICS CFO George Cardoza: RSU Vesting Triggers Tax-Related Share Sale

According to the Form 4 filed with the SEC, George Cardoza, serving as Chief Financial Officer of SOPHiA GENETICS SA, sold 774 ordinary shares in the open market on September 21, 2026, at $8.33 per share. The filing identifies Cardoza's address as c/o Sophia Genetics Inc., 401 Park Drive, Floor 5, Boston, Massachusetts 02215.

The filing states that the shares sold "represent shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on September 18, 2026." The transaction was carried out under a pre-established Rule 10b5-1(c) trading plan adopted by Cardoza. The filing further notes that these sales "do not represent discretionary trades." The Form 4 also indicates that the box confirming a transaction made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan was checked.

After the reported disposal, Cardoza's direct beneficial ownership of ordinary shares in SOPHiA GENETICS SA stood at 308,318 shares, as disclosed in Table I of the filing. No derivative securities transactions were reported in Table II. The form was signed on September 22, 2026, by Elimara Brunetto as Attorney-in-Fact for George Cardoza.

What Was Disclosed

The filing disclosed a single open-market sale of 774 ordinary shares by SOPHiA GENETICS SA's CFO at $8.33 per share on September 21, 2026, executed under a Rule 10b5-1(c) plan to cover RSU vesting-related tax withholding, leaving the CFO with 308,318 shares.